topotecan has been researched along with losartan potassium in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ascari, E; Brugnatelli, S; Comolli, G; Danova, M; Ferrari, S; Porta, C; Pugliese, P; Riccardi, A | 1 |
| Adams, JR; Armitage, JO; Bennett, CL; Demetri, GD; Elting, LS; George, JN; Lembersky, BC; Lyman, GH | 1 |
| Briasoulis, E; Karavassilis, V; Mauri, D; Pavlidis, N; Pentheroudakis, G; Rammou, D; Tzamakou, E | 1 |
| Mufti, GJ | 1 |
| Armstrong, DK; Lane, S; Levin, J; Poulin, R; Spriggs, D | 1 |
| Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E | 1 |
2 review(s) available for topotecan and losartan potassium
| Article | Year |
|---|---|
Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes.
Topics: DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Topotecan | 2004 |
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Topics: Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topotecan | 2005 |
1 trial(s) available for topotecan and losartan potassium
| Article | Year |
|---|---|
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Topotecan | 2005 |
3 other study(ies) available for topotecan and losartan potassium
| Article | Year |
|---|---|
Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients.
Topics: Adult; Aged; Antigens, CD34; Apoptosis; Bromodeoxyuridine; Carcinoma, Small Cell; Cell Cycle; Drug Therapy, Combination; Erythropoietin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lung Neoplasms; Middle Aged; Platelet Count; Recombinant Proteins; Time Factors; Topotecan | 1999 |
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
Topics: Anemia; Antineoplastic Agents; Confidence Intervals; Cost Savings; Cross-Cultural Comparison; Drug Utilization; Erythropoietin; Fee-for-Service Plans; Female; Health Expenditures; Hemoglobinometry; Humans; Male; Managed Care Programs; Medical Oncology; Neoplasms; Odds Ratio; Ovarian Neoplasms; Practice Guidelines as Topic; Practice Patterns, Physicians'; Regression Analysis; Topotecan; United States | 2004 |
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins | 2007 |